Thyroid Cancer

Latest News

Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.
How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

September 16th 2025

Data from a phase 1/2a trial showed that plixorafenib-based care achieved a median PFS of 63.9 months in patients with BRAF-altered thyroid cancers.

A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.
Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

February 9th 2025

A greater proportion of excellent responses were reported without radioiodine than with radioiodine when treating patients with low-risk thyroid cancer.
Thyroidectomy Shows Noninferiority Without Radioiodine in Thyroid Cancer

February 5th 2025

Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer
Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

December 1st 2024

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer
Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

November 1st 2024

Latest CME Events & Activities

More News